SALL4作为卵巢肝样癌诊断指标：一例病例报告及文献复习
SALL4 as an indicator for the diagnosis of hepatoid carcinoma of the ovary: A case report and literature review.
作者信息
Li Jiana, Wu Xiaohua
机构信息
Department of Oncology, Shanghai Medical College Fudan University Shanghai China.
Department of Gynecologic Oncology Fudan University Shanghai Cancer Center Shanghai China.
出版信息
Clin Case Rep. 2023 Jul 30;11(8):e7706. doi: 10.1002/ccr3.7706. eCollection 2023 Aug.
KEY CLINICAL MESSAGE
Primary HCO is a rare, aggressive ovarian malignant tumor, morphologically resembling HCC. SALL4 can be adopted to differentiate HCO from HCC. The serum AFP and CA125 rather than HE4 can be employed as possible biomarkers to track treatment and monitor recurrence.
ABSTRACT
We report a case of a postmenopausal woman presenting with lower abdominal pain and vaginal bleeding. She went through a maximal debulking surgery, and the pathological biopsy revealed hepatoid carcinoma of the ovary (HCO). Immunohistochemical assay demonstrates SALL4 as an indicator to differentiate HCO from hepatocellular carcinoma (HCC).
关键临床信息
原发性肝样卵巢癌是一种罕见的侵袭性卵巢恶性肿瘤，形态上类似于肝细胞癌。SALL4可用于鉴别肝样卵巢癌与肝细胞癌。血清甲胎蛋白和CA125而非人附睾蛋白4可作为追踪治疗和监测复发的潜在生物标志物。
摘要
我们报告一例绝经后女性，表现为下腹部疼痛和阴道出血。她接受了肿瘤细胞减灭术，病理活检显示为卵巢肝样癌（HCO）。免疫组织化学检测显示SALL4是鉴别肝样卵巢癌与肝细胞癌（HCC）的指标。
Zotero 插件